Stay updated on Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and v3.3.3 was removed. No changes to study content or page functionality.
    Difference
    0.0%
    Check dated 2026-01-14T02:55:40.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    19 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    Added a comprehensive Locations section listing participating states for the Cypress-1 trial (rev. v3.3.3).
    Difference
    2%
    Check dated 2025-12-23T17:06:47.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    These changes are minor editorial updates to the Publications section, noting that PubMed publications are automatically populated, and the page revision has moved from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T18:54:34.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The government funding status notice was removed from the page. This change does not modify the study details, eligibility criteria, outcomes, or other substantive content.
    Difference
    0.2%
    Check dated 2025-11-17T18:02:25.000Z thumbnail image
  7. Check
    76 days ago
    Change Detected
    Summary
    No substantive updates were detected; the Study Details, Eligibility Criteria, Interventions, and Outcome measures appear unchanged between versions.
    Difference
    0.3%
    Check dated 2025-11-03T12:42:14.000Z thumbnail image
  8. Check
    105 days ago
    Change Detected
    Summary
    Update includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.
    Difference
    3%
    Check dated 2025-10-05T17:30:24.000Z thumbnail image

Stay in the know with updates to Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pegilodecakin Combo vs Pembrolizumab Alone in NSCLC Clinical Trial page.